Comparative Pharmacology
Head-to-head clinical analysis: XADAGO versus ZELAPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XADAGO versus ZELAPAR.
XADAGO vs ZELAPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
XADAGO (safinamide) is a selective, reversible monoamine oxidase B (MAO-B) inhibitor. It also blocks voltage-dependent sodium and calcium channels, and modulates glutamate release. The MAO-B inhibition increases dopamine levels in the striatum, while the other actions may provide neuroprotective and symptomatic benefits.
Selective and irreversible inhibitor of monoamine oxidase B (MAO-B), which increases dopamine levels in the striatum by blocking its metabolism.
XADAGO (safinamide) 50 mg orally once daily, increased to 100 mg orally once daily based on tolerability and efficacy; take at the same time each day.
1.25 mg sublingually once daily in the morning; may increase to 2.5 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours, supporting once-daily dosing.
Terminal elimination half-life: 2-4 hours (selegiline); due to irreversible MAO-B inhibition, clinical effect persists for 24-72 hours after single dose.
Primarily renal (approximately 70% as unchanged drug and major metabolite O-desmethylsafinamide) and fecal (approximately 30%).
Renal: 70-80% as metabolites (10% as unchanged drug in bile/feces); biliary/fecal: 20-30%.
Category C
Category C
MAO-B Inhibitor
MAO-B Inhibitor